Antares Pharma Inc

Antares Pharma — Investor Presentation (November 2020)

31 slides from Antares Pharma's investor presentation, Nov 12, 2020

  1. Slide 1: November 2020 Investor Presentation

    NASDAQ: ATRS | November 2020 Investor Presentation EX 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate

  3. Slide 3: Executive Team

    Executive Team Robert F. Apple President and CEO Fred Powell EVP and CFO Patrick Shea SVP, Commercial Peter J. Graham EVP, General Counsel, Human Resources and Corporate Secretary Dr. Steven Knapp SVP, Regulatory Affairs and Quality Assurance Ed Tykot SVP, Corporate Business Development Greg DeFilip

  4. Slide 4: Investment Highlights

    Investment Highlights Leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Diversified revenue provides opportunities for continued growth Commercial XYOSTED®, OTREXUP® and NOCDURNA® Commercial Generic EpiPen®, Generi

  5. Slide 5: Long-Term Growth Strategy

    Long-Term Growth Strategy Expand Partnership Opportunities A leader in self-administered injection technology Support life-cycle management solutions Disciplined Capital Allocation Corporate development In-licensing opportunities Enhance Proprietary Portfolio Support research and development Leverag

  6. Slide 6: Rapidly Growing and Diversified Revenue Mix

    Rapidly Growing and Diversified Revenue Mix Proprietary Products Partner Products Development Royalty First 9 months 2018 Revenue $44.7M Revenue $86.0M Revenue $105.5M First 9 months 2019 First 9 months 2020

  7. Slide 7: Proprietary Products

    Proprietary Products (desmopressin acetate) sublingual tablet

  8. Slide 8: Patient-Centric Innovation Drives Strategy

    Patient-Centric Innovation Drives Strategy Targeting two therapeutic areas with significant market opportunities UROLOGY & ENDOCRINOLOGY Focus on patient populations with high unmet needs Target addressable physician audiences for efficient commercialization Identify and develop innovative, differen

  9. Slide 9: XYOSTED (testosterone enanthate) for injection

    *Studied for 52 weeks when taken every week, as directed. Achieving desired blood levels may require dose adjustments at Week 7 based upon Week 6 blood levels. Some patients fell below minimum level of 300 ng/dL despite dose adjustments. Innovative self-delivery of testosterone (T) replacement thera

  10. Slide 10: Testosterone Market

    Testosterone Market Once Weekly Painless Efficacious Steady PK No Risk of Transfer Once Weekly Painless Steady PK Low Risk of Transfer Intramuscular Injection Topical Gels IQVIA Data

  11. Slide 11: XYOSTED Quarterly TRx Growth

    XYOSTED® Quarterly TRx Growth ~185,000 XYOSTED TRx’s (as of October 23, 2020) Written by ~6,500 different physicians (as of October 23, 2020) 3Q 2020 TRx’s increased ~15% sequentially IQVIA Calculated Packaged Units 43,997 38,274 27,702 19,183 11,001 4,003 33,164

  12. Slide 12: XYOSTED Broad Utilization Across Specialties

    XYOSTED® Broad Utilization Across Specialties IQVIA Data

  13. Slide 13: Multiple Channels Directed at Key XYOSTED Targets

    Multiple Channels Directed at Key XYOSTED® Targets STEADYCare: Competitive co-pay assistance (up to $125/month) CoverMyMeds.com: Office support to drive rapid claim adjudication First-Fill-Free and product sample programs Social Media and Digital Engagement Enduring Materials and Sales Assets Congre

  14. Slide 14: Focused Sales Effort to Optimize Current Portfolio

    Branded TRT and RA/MTX market Cover 75% of the TRT prescribers in the top 3 deciles Every territory has 120-150 top decile prescriber 90% of OTREXUP® volume is covered Highly tenured sales team with ~15-20 years of experience 79 SARs, 10 RSMs, NSD (90 FTE) Flexible ‘virtual’ team (6 PSR’s) patient s

  15. Slide 15: In-Licensed: NOCDURNA (desmopressin acetate)

    FDA-approved, on market vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times a night to void Rapidly dissolving sublingual tablet taken once-a-day, one hour prior to sleep Short-acting desmopressins are considered standard-of-ca

  16. Slide 16: Antares Assets in Development

    ATRS-1902 Urology Asset Antares Assets in Development ATRS-1901: Endocrinology Asset Completed Pre-IND meeting with FDA Expected IND filing in 1H 2021 ATRS-1902: Urology Asset Pre-IND meeting with FDA in 4Q 2020 Expected IND filing in 2H 2021

  17. Slide 17: Partner Business

    RP» antares pharma Partner Business teva amas ‘Worsta ~=GE> November2020 17

  18. Slide 18: Drug/Device Combination Product Partner

    Drug/Device Combination Product Partner Deep Device Knowledge Extensive Regulatory Expertise and Success Tailored Durable Asset Development PHARMACEUTICAL TECHNOLOGY PARTNER Partner Business Revenue (in millions)

  19. Slide 19: Commercial Experience: Teva's Generic EpiPen

    Commercial Experience Teva’s Generic EpiPen FDA-approved as therapeutically equivalent to Mylan’s EpiPen® and fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales EpiPen, Sr. limited commercial l

  20. Slide 20: Generic EpiPen Quarterly TRx Prescription Trends

    Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions

  21. Slide 21: Generic Forteo (teriparatide)

    Generic Forteo® (teriparatide) Teva awaiting FDA approval for their ANDA for generic Forteo® Expect six-month exclusivity Fully substitutable at pharmacy Teva launched in 11 European countries and Israel and Canada Forteo® 2019 revenue $646 million in U.S. $759 million in ROW by Lilly ATRS will supp

  22. Slide 22: Selatogrel

    selatogrel Global Development Agreement with Idorsia Pharmaceuticals for selatogrel, a New Chemical Entity, with the QuickShot auto injector Selatogrel is a fast acting and highly selective P2Y12 receptor antagonist intended for the treatment of suspected Acute Myocardial Infarction (AMI) Phase 2 da

  23. Slide 23: Myocardial Infarction Market Opportunity

    Myocardial Infarction Market Opportunity 1. Mozaffarian D et al. Circulation 2016 ~750,000 occurrences of new or recurrent MI1 annually 550,000 have a first MI + 200,000 have a recurrent MI Onset of action of all oral P2Y12 inhibitors may be delayed by >6 hours in the setting of acute myocardial inf

  24. Slide 24: Diversified Product Portfolio

    Diversified Product Portfolio Testosterone Methotrexate Sumatriptan Epinephrine Hydroxyprogesterone Teriparatide Teriparatide Exenatide P2Y12 Receptor Antagonist Undisclosed Undisclosed Undisclosed XYOSTED® OXTREXUP® SUMATRIPTAN EPINEPHRINE MAKENA® TERIPARATIDE (EU) TERIPARATIDE (U.S.) EXENATIDE SEL

  25. Slide 25: Financial Overview

    Financial Overview

  26. Slide 26: Revenue Growth and 2020 Projections

    +17% vs. 2017 +95% vs. 2018 Revenue Growth and 2020 Projections Projected CAGR of 22%* * Based on mid-point of 2020 revenue guidance +14% vs. 2015 Revenue Guidance

  27. Slide 27: Income Statement Summary

    Income Statement Summary (in millions, except EPS) 3Q 2020 3Q 2019 Increase (Decrease) 9M 2020 9M 2019 Increase (Decrease) Revenue 40.0 34.3 17% 105.5 86.0 23% Gross Profit 23.5 21.2 11% 61.4 49.6 24% Margin 59% 62% --- 58% 58% --- Total Operating Expenses 17.6 19.2 (8)% 53.9 54.2 0% Net Income / (L

  28. Slide 28: Value Creation

    RP» antares Value Creation

  29. Slide 29: Antares Pharma: Value Proposition

    Antares Pharma: Value Proposition Diverse portfolio of commercialized products Multiple growth drivers Continued XYOSTED® prescription growth Continued generic EpiPen® prescription growth Relaunch of NOCDURNA® Potential FDA approval and U.S. launch of Teva’s generic teriparatide Pfizer development p

  30. Slide 30: Value Enhancing Catalysts in the Near-Term

    Value Enhancing Catalysts in the Near-Term 2H 2021 2020 revenue guidance of $135-155M Teva’s U.S. approval and launch of generic teriparatide Expect Pre-IND meeting with FDA for proprietary urology asset Teva’s launch of generic teriparatide in 11 countries in EU, Canada and Israel International dis

  31. Slide 31: making medicines, better”

    making medicines, better” feed.

Antares Pharma — Investor Presentation (November 2020) on 6ix